Physician profile
Heather Scott
NPI 1659742161
$8,124.12
in general payments reported to CMS, 2019-2025
29 companies · $2,207 in 2025
The $2,207 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $786 · 2022: $1,441 · 2023: $2,046 · 2024: $1,644 · 2025: $2,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,808 · Education: $89.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,808.08 |
| Education | $89.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,471.96 | 2021-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $1,252.92 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $773.38 | 2021-2025 | Dupixent |
| Csl Behring | $696.30 | 2022-2025 | Hizentra, Haegarda, Andembry |
| Genzyme Corporation | $535.56 | 2021-2025 | |
| Genentech USA, INC. | $410.51 | 2021-2025 | Xolair |
| Pfizer INC. | $327.87 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $308.56 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $270.70 | 2021-2025 | Hyqvia, Takhzyro, Cuvitru |
| Amgen INC. | $224.47 | 2022-2025 | Tezspire |
| Incyte Corporation | $215.60 | 2022-2025 | Opzelura |
| Cycle Pharmaceuticals INC | $210.07 | 2024-2025 | Sajazir |
| Grifols USA, LLC | $176.24 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Kaleo, INC. | $174.16 | 2021-2023 | Auvi-Q |
| Galderma Laboratories, L.P. | $173.35 | 2024-2025 | Nemluvio |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $152.98 | 2021 | |
| Biocryst US Sales Co., LLC | $150.93 | 2023-2025 | Orladeyo |
| Ionis Pharmaceuticals, INC. | $99.68 | 2025 | Dawnzera |
| Lilly USA, LLC | $97.51 | 2025 | Ebglyss |
| Pharming Healthcare, INC. | $86.51 | 2021-2024 | Ruconest |
| Abbvie INC. | $78.15 | 2022-2023 | |
| Optinose US, INC. | $72.81 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $38.73 | 2025 | Xhance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.33 | 2021-2023 | Spiriva Respimat |
| Organon LLC | $25.59 | 2025 | Vtama |
| Octapharma USA, INC. | $19.33 | 2021 | |
| Leo Pharma INC. | $18.14 | 2022 | |
| Bio Products Laboratory USA, INC. | $17.90 | 2022 | |
| Uswm, LLC | $16.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.